We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Replimune Group Inc (REPL) USD0.001

Sell:$15.45 Buy:$15.48 Change: $0.96 (6.61%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.96 (6.61%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.96 (6.61%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The Company is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

Contact details

500 Unicorn Park Dr
United States
+1 (781) 2229600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$685.95 million
Shares in issue:
47.21 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Robert Coffin
    President, Director, Chief Research & Development Officer
  • Philip Astley-Sparke
    Chief Executive Officer, Director
  • Jean Franchi
    Chief Financial Officer, Treasurer
  • Colin Love
    Chief Operating Officer
  • Pamela Esposito
    Chief Business Officer
  • Tanya Lewis
    Chief Development Operations
  • Sushil Patel
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.